The measurement of 14-3-3 proteins in the cerebrospinal fluid has already been developed in neurology as a potential biomarker for neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-Jakob disease, or amyotrophic lateral sclerosis6,51,52. This evidence concerns the gene YWHAQ and Parkinson disease.